Masters Pharmaceuticals

Jun 9, 2015

Alliance Pharma announces its results for 2014 Masters Speciality Pharma, a leading international pharmaceutical company specialising in advanced medicines supply, today announced the strengthening of its capabilities in Brazil through its acquisition of Masters Distribution Brazil. The new company, located in São Caetano do Sul, São Paulo, will become part of the Master Speciality Pharma Group, and contribute to the group’s future expansion and growth plans in Latin America. Since its incorporation eight years ago, Masters Pharmaceuticals Ltda, Brazil – the regional subsidiary of the Masters Speciality Pharma group – has focused on early-access programs through the named patient supply (NPS) of unlicensed medicines to patients and government institutions in the country. With continuing high demand and growth potential in the region, the acquisition of Masters Distribution Brazil represents an important step towards the further diversification of its business activities in the country. Masters Distribution Brazil is already fully compliant with the local AFE (Autorizacao de Funcionamento de Empresa) and AE (Autorização Especial) regulations, which permit the registration of human medicines in all therapy classes. This enables the business to register its own products as well as manage third-party products through distributorship and licensing arrangements. “This is an exciting acquisition for the Masters Speciality Pharma group,” said Lynda Foster, CEO of Masters Speciality Pharma. “Masters Distribution Brazil is ideally positioned to provide importation, distribution and storage services, and to export medicinal products from Brazil to other countries. It will now become a dedicated regional hub in addition to the group’s existing distribution centres in the UK and Florida,” concluded Foster. Notes for editors The pharmaceutical market in Brazil The pharmaceutical market in Brazil has been the focus of great interest since it became one of the few countries in the world to provide a universal, free public healthcare system 20 years ago. The implementation of Brazil’s national health service, Sistema Único de Saúde (SUS), which is responsible for providing a wide range of medical treatments, has made the country attractive to pharmaceutical companies despite its regulatory complexities. Brazil is the eighth-largest pharma market globally, worth approximately US$26.4 billion and estimated to grow to US$50 billion in the next four years (IMS Health Data). View source version on businesswire.com: http://www.businesswire.com/news/home/20150609005028/en/ Catalyst Comms for Masters Speciality Pharma Sue Glanville/Cate Bonthuys